Novartis seeks to block Biocon's Galvus copies in India
This article was originally published in Scrip
Executive Summary
Novartis has moved the Delhi High Court against Biocon, alleging infringement of its patent concerning the DPP-4 inhibitor for diabetes, vildagliptin, its second such action against an Indian firm over the product in the recent past.